Abstract | PURPOSE: EXPERIMENTAL DESIGN: We used electrochemiluminescence immunoassay with mAb MH8-11 to determine circulating aminopeptidase N/CD13 levels in 90 healthy volunteers and 90 patients with NSCLC. Circulating aminopeptidase N/CD13 levels were measured in sera taken before treatment and evaluated for a relationship with clinical outcomes. RESULTS: A significant correlation was found between tumor progression and serum aminopeptidase N/CD13 concentrations (r=0.23, P=0.029). High serum aminopeptidase N/CD13 levels (n=17) were associated with advanced stage (P=0.004) or poor performance status (P=0.001). The overall survival rate for patients with high serum aminopeptidase N/CD13 levels (n=17) was significantly less than that of patients with low serum aminopeptidase N/CD13 levels (n=73, P<0.0001). In a multivariate survival analysis in patients with NSCLC, serum aminopeptidase N/CD13 levels had an independent influence on survival (relative risk, 4.1; 95% confidence interval, 1.9-8.8). CONCLUSIONS: Our data suggest that a high level of circulating aminopeptidase N/CD13 at diagnosis is an independent prognostic factor in patients with NSCLC.
|
Authors | Haruyasu Murakami, Akihito Yokoyama, Keiichi Kondo, Shuhei Nakanishi, Nobuoki Kohno, Masayuki Miyake |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 11
Issue 24 Pt 1
Pg. 8674-9
(Dec 15 2005)
ISSN: 1078-0432 [Print] United States |
PMID | 16361553
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- CD13 Antigens
|
Topics |
- Antibodies, Monoclonal
(immunology)
- CD13 Antigens
(blood, immunology)
- Carcinoma, Non-Small-Cell Lung
(diagnosis, mortality, pathology)
- Disease Progression
- Female
- Humans
- Lung Neoplasms
(diagnosis, mortality, pathology)
- Male
- Prognosis
|